All In Biotech

BLA 761440 · Glaxosmithkline LLC

Blenrep

Belantamab Mafodotin-Blmf · Injection

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Oct 23, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

72

10 Phase 3, 16 recruiting

FAERS reports

3,107

2,738 serious, 1,042 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: OCULAR TOXICITY • BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred [see Warnings and Precautions ( 5.1 )] . • Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 )] . • Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS) [see Warnings and...

What it is approved for

From the label in effect Oct 23, 2025.

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP, a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate, is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. ( 1 )

Mechanism: Belantamab mafodotin‑blmf is an antibody‑drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is mcMMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin‑blmf is internalized followed by release of the cytotoxic agent (cys‑mcMMAF) via proteolytic cleavage. The released cys‑mcMMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis. Belantamab mafodotin‑blmf had antitumor activity in multiple...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 23, 2025 Original approval · Type 2 - New Active Ingredient OrphanLabelLetter
1 products under this application
  • BLENREP · BELANTAMAB MAFODOTIN-BLMF 70MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Belantamab Mafodotin" as an intervention, any sponsor and status, largest first.

All 72 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • keratopathy856
  • visual acuity reduced800
  • death586
  • plasma cell myeloma455
  • dry eye404
  • night blindness317
  • vision blurred204
  • photophobia189
  • foreign body sensation in eyes186
  • ocular toxicity168
  • visual impairment131
  • punctate keratitis130

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20193
2020185
2021776
20221,149
2023270
202482
2025160
2026482

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.